All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 1.5%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Prothena that you should be aware of.